Sulfotyrosine-Mediated Recognition of Human Thrombin by a Tsetse Fly Anticoagulant Mimics Physiological Substrates.

Glossina morsitans X-ray crystallography anticoagulant coagulation inhibitor macromolecular recognition post-translational modification protein-protein interaction three-dimensional structure thrombin inhibitor tyrosine sulfation

Journal

Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030

Informations de publication

Date de publication:
21 01 2021
Historique:
received: 18 05 2020
revised: 22 07 2020
accepted: 05 10 2020
pubmed: 24 10 2020
medline: 27 8 2021
entrez: 23 10 2020
Statut: ppublish

Résumé

Despite possessing only 32 residues, the tsetse thrombin inhibitor (TTI) is among the most potent anticoagulants described, with sub-picomolar inhibitory activity against thrombin. Unexpectedly, TTI isolated from the fly is 2000-fold more active and 180 Da heavier than synthetic and recombinant variants. We predicted the presence of a tyrosine O-sulfate post-translational modification of TTI, prompting us to investigate the effect of the modification on anticoagulant activity. A combination of chemical synthesis and functional assays was used to reveal that sulfation significantly improved the inhibitory activity of TTI against thrombin. Using X-ray crystallography, we show that the N-terminal sulfated segment of TTI binds the basic exosite II of thrombin, establishing interactions similar to those of physiologic substrates, while the C-terminal segment abolishes the catalytic activity of thrombin. This non-canonical mode of inhibition, coupled with its potency and small size, makes TTI an attractive scaffold for the design of novel antithrombotics.

Identifiants

pubmed: 33096052
pii: S2451-9456(20)30381-0
doi: 10.1016/j.chembiol.2020.10.002
pii:
doi:

Substances chimiques

Anticoagulants 0
Antithrombin Proteins 0
Insect Proteins 0
tsetse thrombin inhibitor 0
tyrosine O-sulfate 29166358BF
Tyrosine 42HK56048U
Thrombin EC 3.4.21.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-33.e8

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

Bárbara M Calisto (BM)

ESRF - The European Synchrotron, Structural Biology Group, 38000 Grenoble, France; ALBA Synchrotron, 08290 Cerdanyola del Vallès, Spain.

Jorge Ripoll-Rozada (J)

IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, 4200-135 Porto, Portugal; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.

Luke J Dowman (LJ)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.

Charlotte Franck (C)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.

Stijn M Agten (SM)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.

Benjamin L Parker (BL)

Department of Physiology, University of Melbourne, Melbourne, VIC 3010, Australia.

Rita Carvalho Veloso (RC)

LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, 4169-007 Porto, Portugal.

Nuno Vale (N)

IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135 Porto, Portugal; Laboratory of Pharmacology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.

Paula Gomes (P)

LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, 4169-007 Porto, Portugal.

Daniele de Sanctis (D)

ESRF - The European Synchrotron, Structural Biology Group, 38000 Grenoble, France.

Richard J Payne (RJ)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia; Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia.

Pedro José Barbosa Pereira (PJB)

IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, 4200-135 Porto, Portugal; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal. Electronic address: ppereira@ibmc.up.pt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH